Mononuclear cell transcriptome changes associated with dimethyl fumarate in MS

about

Mononuclear cell transcriptome changes associated with dimethyl fumarate in MS

Item

http://www.wikidata.org/entity/Q57144024

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована в липні 2018

@uk

name

Mononuclear cell transcriptome changes associated with dimethyl fumarate in MS

@en

Mononuclear cell transcriptome changes associated with dimethyl fumarate in MS

@nl

type

Item

label

Mononuclear cell transcriptome changes associated with dimethyl fumarate in MS

@en

Mononuclear cell transcriptome changes associated with dimethyl fumarate in MS

@nl

prefLabel

Mononuclear cell transcriptome changes associated with dimethyl fumarate in MS

@en

Mononuclear cell transcriptome changes associated with dimethyl fumarate in MS

@nl

P1476

Mononuclear cell transcriptome changes associated with dimethyl fumarate in MS

@en

P2093

Arie R Gafson

http://www.w3.org/2001/XMLSchema#string

Maria T Cencioni

http://www.w3.org/2001/XMLSchema#string

Paul M Matthews

http://www.w3.org/2001/XMLSchema#string

Richard Nicholas

http://www.w3.org/2001/XMLSchema#string

Sergio E Baranzini

http://www.w3.org/2001/XMLSchema#string

Wim van Hecke

http://www.w3.org/2001/XMLSchema#string

P2860

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

The MOS 36-ltem Short-Form Health Survey (SF-36)

Is it time to target no evident disease activity (NEDA) in multiple sclerosis?

Utilization of Dimethyl Fumarate and Related Molecules for Treatment of Multiple Sclerosis, Cancer, and Other Diseases

Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2

HTSeq--a Python framework to work with high-throughput sequencing data

Personal omics profiling reveals dynamic molecular and medical phenotypes

Delayed-release dimethyl fumarate and disability assessed by the Multiple Sclerosis Functional Composite: Integrated analysis of DEFINE and CONFIRM.

Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies.

The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force.

P304

e470

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1212/NXI.0000000000000470

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Kicheol Kim

P577

2018-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30283812

http://www.w3.org/2001/XMLSchema#string

P921

transcriptome

P932

6168332

http://www.w3.org/2001/XMLSchema#string